Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge

Vaccine

Volumn 33, Issue 39, 2015, Pages 5155-5162

  Kingstad Bakke, Brock ^a   Kamlangdee, Attapon ^a   Osorio, Jorge E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

HPAI; Mice; Mucosal; Raccoonpox virus; Vaccine

Indexed keywords

AVIAN INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; RACCOONPOX VIRUS EXPRESSING HIGHLY PATHOGENIC AVIAN H5N1 INFLUENZA NEURAMINIDASE; UNCLASSIFIED DRUG; DRUG CARRIER; INFLUENZA VACCINE; NA PROTEIN, INFLUENZA A VIRUS; RECOMBINANT VACCINE; SIALIDASE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; IMMUNE RESPONSE; IN VITRO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS ENTRY; ANIMAL; BLOOD; DISEASE MODEL; FEMALE; GENE VECTOR; GENETICS; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG; LYMPHOCYTE DEPLETION; MUCOSAL DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE INFECTIONS; ORTHOPOXVIRUS; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNITY, HETEROLOGOUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; LUNG; LYMPHOCYTE DEPLETION; MICE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; ORTHOPOXVIRUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84941730542     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.005     Document Type: Article

References (52)

1. Economic and social impact of epidemic and pandemic influenza. Vaccine 2006, 24:6776-6778.
2. Meltzer M.I., Cox N.J., Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5:659-671.
3. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987, 56:365-394.
4. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 1983, 37:529-549.
5. Colman P.M. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 1994, 3:1687-1696.
6. Drzeniek R., Gauhe A. Differences in substrate specificity of myxovirus neuraminidases. Biochem Biophys Res Commun 1970, 38:651-656.
7. Liu C., Eichelberger M.C., Compans R.W., Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995, 69:1099-1106.
8. Kingstad-Bakke B., Brewoo J.N., Mai le Q., Kawaoka Y., Osorio J.E. Effects of route and coadministration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice. Vaccine 2012, 30:6402-6408.
9. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010, 84:1489-1503.
10. Esposito J.J., Knight J.C., Shaddock J.H., Novembre F.J., Baer G.M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology 1988, 165:313-316.
11. Herman Y.F. Isolation and characterization of a naturally occurring poxvirus of raccoons. Bacteriol Proc 64th ANnual Meeting Amer Soc Microbiol 1964, 117.
12. Osorio J.E., Frank R.S., Moss K., Taraska T., Powell T., Stinchcomb D.T. Raccoon poxvirus as a mucosal vaccine vector for domestic cats. J Drug Target 2003, 11:463-470.
13. Esposito J.J., Chandler F.W., Baer G.M. Oral immunization of animals with raccoon poxvirus expressing rabies virus glycoprotein. Vaccines 1989, 89:403-408.
14. Rocke T.E., Pussini N., Smith S.R., Williamson J., Powell B., Osorio J.E. Consumption of baits containing raccoon pox-based plague vaccines protects black-tailed prairie dogs (Cynomys ludovicianus). Vector Borne Zoonotic Dis 2010, 10:53-58.
15. Hwa S.H., Iams K.P., Hall J.S., Kingstad B.A., Osorio J.E. Characterization of recombinant raccoonpox vaccine vectors in chickens. Avian Dis 2010, 54:1157-1165.
16. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80:1959-1964.
17. Kamlangdee A., Kingstad-Bakke B., Anderson T.K., Goldberg T.L., Osorio J.E. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol 2014, 88:13300-13309.
18. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78:12665-12667.
19. Ohuchi M., Asaoka N., Sakai T., Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 2006, 8:1287-1293.
20. Kilbourne E.D., Johansson B.E., Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci U S A 1990, 87:786-790.
21. McNulty M.S., Allan G.M., Adair B.M. Efficacy of avian influenza neuraminidase-specific vaccines in chickens. Avian Pathol 1986, 15:107-115.
22. Webster R.G., Reay P.A., Laver W.G. Protection against lethal influenza with neuraminidase. Virology 1988, 164:230-237.
23. Schulman J.L., Khakpour M., Kilbourne E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968, 2:778-786.
24. Schulman J.L. The role of antineuraminidase antibody in immunity to influenza virus infection. Bull World Health Organ 1969, 41:647-650.
25. Bottex C., Burckhart M.F., Fontanges R. Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: results of mouse protection experiments. Arch Virol 1981, 70:83-89.
26. Kilbourne E.D., Laver W.G., Schulman J.L., Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 1968, 2:281-288.
27. Kilbourne E.D., Couch R.B., Kasel J.A., Keitel W.A., Cate T.R., Quarles J.H., et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995, 13:1799-1803.
28. Kilbourne E.D., Pokorny B.A., Johansson B., Brett I., Milev Y., Matthews J.T. Protection of mice with recombinant influenza virus neuraminidase. J Infect Dis 2004, 189:459-461.
29. Johansson B.E., Matthews J.T., Kilbourne E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998, 16:1009-1015.
30. Rockman S., Brown L.E., Barr I.G., Gilbertson B., Lowther S., Kachurin A., et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 2013, 87:3053-3061.
31. Martinet W., Saelens X., Deroo T., Neirynck S., Contreras R., Min Jou W., et al. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur J Biochem 1997, 247:332-338.
32. Johansson B.E., Price P.M., Kilbourne E.D. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine 1995, 13:841-845.
33. Johansson B.E. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999, 17:2073-2080.
34. Johansson B.E., Pokorny B.A., Tiso V.A. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002, 20:1670-1674.
35. Deroo T., Jou W.M., Fiers W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996, 14:561-569.
36. Chen Z., Sahashi Y., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 1998, 16:1544-1549.
37. Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H., et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 1999, 80(Pt 10):2559-2564.
38. Chen Z., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 1999, 17:653-659.
39. Chen J., Fang F., Li X., Chang H., Chen Z. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 2005, 23:4322-4328.
40. Li X., Fang F., Song Y., Yan H., Chang H., Sun S., et al. Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. DNA Cell Biol 2006, 25:197-205.
41. Zhang F., Chen J., Fang F., Zhou Y., Wu J., Chang H., et al. Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol 2005, 24:758-765.
42. Qiu M., Fang F., Chen Y., Wang H., Chen Q., Chang H., et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. Biochem Biophys Res Commun 2006, 343:1124-1131.
43. Hessel A., Schwendinger M., Fritz D., Coulibaly S., Holzer G.W., Sabarth N., et al. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS ONE 2010, 5:e12217.
44. Sylte M.J., Hubby B., Suarez D.L. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 2007, 25:3763-3772.
45. Torrieri-Dramard L., Lambrecht B., Ferreira H.L., Van den Berg T., Klatzmann D., Bellier B. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther 2011, 19:602-611.
46. Quan F.S., Kim M.C., Lee B.J., Song J.M., Compans R.W., Kang S.M. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 2012, 430:127-135.
47. Easterbrook J.D., Schwartzman L.M., Gao J., Kash J.C., Morens D.M., Couzens L., et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 2012, 432:39-44.
48. Nayak B., Kumar S., DiNapoli J.M., Paldurai A., Perez D.R., Collins P.L., et al. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 2010, 84:2408-2420.
49. Reay P.A., Jones I.M., Gotch F.M., McMichael A.J., Brownlee G.G. Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes. Virology 1989, 170:477-485.
50. Epstein S.L., Misplon J.A., Lawson C.M., Subbarao E.K., Connors M., Murphy B.R. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J Immunol 1993, 150:5484-5493.
51. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005, 353:1363-1373.
52. O'Brien K.B., Schultz-Cherry S., Knoll L.J. Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection. J Virol 2011, 85:8680-8688.